SCHEMBL13721373

SCHEMBL13721373

CCCN1CCC(C(C(N)=O)(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM3 P20309 3/20 0.60
▸ DRD2 P14416 3/20 0.60
▸ CHRM2 P08172 2/20 0.60
▸ ADRB2 P07550 2/20 0.60
▸ CHRM4 P08173 1/20 0.60
▸ ADRB1 P08588 1/20 0.60
▸ CHRM5 P08912 1/20 0.60
▸ ADRA2A P08913 1/20 0.60
▸ CHRM1 P11229 1/20 0.60
▸ KCNE1 P15382 1/20 0.60
▸ ADRA2B P18089 1/20 0.60
▸ ADRA2C P18825 1/20 0.60
▸ HRH2 P25021 1/20 0.60
▸ HTR2A P28223 1/20 0.60
▸ SLC6A4 P31645 1/20 0.60
▸ ADRA1A P35348 1/20 0.60
▸ OPRM1 P35372 1/20 0.60
▸ OPRK1 P41145 1/20 0.60
▸ HTR2B P41595 1/20 0.60
▸ KCNQ1 P51787 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13785555 0.93 KCNH2 (0.58) CHRM3DRD2CHRM2ADRB2CHRM4
SCHEMBL14128532 0.90 CHRM3 (0.56) CHRM3DRD2CHRM2ADRB2CHRM4
SCHEMBL11478311 0.90 CHRM3 (0.56) CHRM3DRD2CHRM2ADRB2CHRM4
SCHEMBL13590293 0.88 CHRM3 (0.61) CHRM3DRD2CHRM2ADRB2CHRM4
SCHEMBL13590341 0.88 CHRM3 (0.61) CHRM3DRD2CHRM2ADRB2CHRM4
SCHEMBL13785557 0.88 DRD2 (0.47) CHRM3DRD2CHRM2ADRB2CHRM4
SCHEMBL959792 0.88 CHRM3 (0.61) CHRM3DRD2CHRM2ADRB2CHRM4
SCHEMBL13590079 0.88 CHRM3 (0.61) CHRM3DRD2CHRM2ADRB2CHRM4
SCHEMBL13592297 0.88 CHRM3 (0.61) CHRM3DRD2CHRM2ADRB2CHRM4
SCHEMBL13590478 0.88 CHRM3 (0.61) CHRM3DRD2CHRM2ADRB2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572918-B2 Prepared in high yield and high purity without the need for isolation of intermediates and chromatographic purification; useful as muscarinic receptor antagonists; 4-{N-[7-(3-(S)-1-carbamoyl-1,1-diphenylmethyl)-pyrrolidin-1-yl)-hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)-piperidine THERAVANCE, INC. (US) 2009-08-11 — — US disclosed
Send feedback